Cohance Lifesciences has received five observations from the United States Food and Drug Administration (USFDA) following an inspection of its Hyderabad manufacturing facility.

The company stated that the findings do not involve data integrity issues, a distinction that regulators and industry analysts often weigh heavily, as data integrity violations can trigger more prolonged compliance reviews and import alerts. Cohance confirmed it is working on corrective and preventive actions (CAPAs) to address the regulator's concerns and will respond to the USFDA within the prescribed timeframe, typically within 15 working days of receiving the Form 483.

USFDA inspections of pharmaceutical manufacturing facilities typically evaluate compliance with Current Good Manufacturing Practices (CGMP). Observations are documented on Form 483 when investigators identify conditions that may constitute violations of the Food, Drug, and Cosmetic Act. The number and nature of observations can vary, and companies are generally given an opportunity to respond with corrective measures before further regulatory action, such as warning letters or import alerts, is considered.

Cohance Lifesciences is a pharmaceutical company with operations in India, formed through Advent International's combination of Suven Pharmaceuticals and Cohance's contract development and manufacturing operations. Its Hyderabad facility is part of a manufacturing network in a city that serves as one of India's largest pharmaceutical production hubs. India is a major global supplier of generic medicines, and USFDA compliance at Indian facilities is closely monitored given the volume of drug products exported to the United States. The company's stock is tracked on Indian markets.

The original report was published by CNBC-TV18 Markets.